Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Clinical Trial Size in Orphan and Rare Diseases

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Dec 03, 2023 10:05pm

119 Views

Post# 35766393

RE:RE:RE:RE:RE:RE:RE:RE:RE:Clinical Trial Size in Orphan and Rare Diseases

OK so that gives us hope. Can u or Norman provide a link to the trials with less than 20 patients that were granted AA. I would like to add that to my files. Also one would think that onc could apply for AA with the mbc as one would think that they would qualify given the results and unmet need.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing